Olson-Kennedy Johanna, Durazo-Arvizu Ramon, Wang Liyuan, Wong Carolyn F, Chen Diane, Ehrensaft Diane, Hidalgo Marco A, Chan Yee-Ming, Garofalo Robert, Radix Asa E, Rosenthal Stephen M
Division of Adolescent and Young Adult Medicine, Children's Hospital, Los Angeles, California.
Department of Pediatrics, University of Southern California, Los Angeles, California.
medRxiv. 2025 May 16:2025.05.14.25327614. doi: 10.1101/2025.05.14.25327614.
Medical interventions for youth with gender dysphoria can include the use of gonadotropin releasing hormone analogs (GnRHas) for suppression of endogenous puberty. This analysis aimed to understand the impact of medical intervention initiated with GnRHas on psychological well-being among youth with gender dysphoria over 24 months.
Participants were enrolled as part of the Trans Youth Care United States Study. Eligibility criteria for youth included a diagnosis of Gender Dysphoria and pubertal initiation. Youth with precocious puberty or pre-existing osteoporosis were ineligible. Youth reported on depressive symptoms, emotional health and suicidality at baseline, 6, 12, 18 and 24 months after initiation of GnRHas. Parent/caretaker completed the Child Behavior Checklist at baseline, 12 and 24 months after initiation of GnRHas. Latent Growth-Curve Models analyzed trajectories of change over the 24-month period.
Ninety-four youth aged 8-16 years (mean=11.2 y) were predominately Non-Hispanic White (56%), early pubertal (86%) and assigned male at birth (52%). Depression symptoms, emotional health and CBCL constructs did not change significantly over 24 months. At no time points were the means of depression, emotional health or CBCL constructs in a clinically concerning range.
Participants initiating medical interventions for gender dysphoria with GnRHas have self- and parent-reported psychological and emotional health comparable with the population of adolescents at large, which remains relatively stable over 24 months. Given that the mental health of youth with gender dysphoria who are older is often poor, it is likely that puberty blockers prevent the deterioration of mental health.
针对性别焦虑症青少年的医学干预措施可包括使用促性腺激素释放激素类似物(GnRHas)来抑制内源性青春期。本分析旨在了解以GnRHas开始的医学干预对性别焦虑症青少年24个月内心理健康的影响。
参与者作为美国跨性别青少年护理研究的一部分被招募。青少年的纳入标准包括性别焦虑症诊断和青春期开始。性早熟或已有骨质疏松症的青少年不符合条件。青少年在开始使用GnRHas后的基线、6个月、12个月、18个月和24个月报告抑郁症状、情绪健康和自杀倾向。父母/照顾者在开始使用GnRHas后的基线、12个月和24个月完成儿童行为检查表。潜在生长曲线模型分析了24个月期间的变化轨迹。
94名年龄在8至16岁(平均 = 11.2岁)的青少年主要为非西班牙裔白人(56%),青春期早期(86%),出生时被指定为男性(52%)。抑郁症状、情绪健康和儿童行为检查表各项指标在24个月内没有显著变化。在任何时间点,抑郁、情绪健康或儿童行为检查表各项指标的均值均未处于临床关注范围。
开始使用GnRHas对性别焦虑症进行医学干预的参与者自我报告和父母报告的心理及情绪健康与广大青少年群体相当,且在24个月内保持相对稳定。鉴于年龄较大的性别焦虑症青少年心理健康往往较差,青春期阻滞剂可能预防了心理健康的恶化。